Atorvastatin DC Granules are pharmaceutical formulation granules containing atorvastatin calcium in a controlled granular format intended for direct-compression applications. Atorvastatin Calcium is a synthetic active pharmaceutical ingredient belonging to the statin class and is commonly formulated into oral solid dosage forms. The USP-NF monograph identifies Atorvastatin Calcium with the molecular formula C₆₆H₆₈CaF₂N₄O₁₀ and molecular weight 1155.36 g/mol for the anhydrous form. The USP definition specifies not less than 98.0% and not more than 102.0% atorvastatin calcium, calculated on an anhydrous and solvent-free basis.
The term DC Granules refers to a finished granular formulation designed for direct compression processing. Direct compression requires appropriate material and blend properties because flow, particle size, density, compressibility, compactability and blend uniformity can affect tablet manufacturing. Pharmaceutical research specifically identifies flow and compactability as important properties for successful direct-compression processing.
Atorvastatin DC Granules are granulated pharmaceutical formulations containing atorvastatin calcium together with selected excipients and processing components. The granulation approach converts the formulation into a controlled particulate form suitable for downstream compression or related oral solid dosage manufacturing processes.
Unlike the raw atorvastatin calcium API, finished Atorvastatin DC Granules are a formulation system. Their physical characteristics depend on the API particle properties, excipient selection, granulation process, binder system, granule size distribution, moisture level and other manufacturing parameters.
The finished granules can therefore be evaluated for both chemical quality and physical processing characteristics.
Atorvastatin Calcium is the calcium salt of atorvastatin. USP-NF lists the anhydrous material as C₆₆H₆₈CaF₂N₄O₁₀ with molecular weight 1155.36 g/mol and CAS Number 134523-03-8. USP also identifies a trihydrate form with CAS 344423-98-9 and molecular weight 1209.41 g/mol.
Because different solid forms can have different chemical and physical characteristics, the exact form used in the finished granules should correspond to the approved raw-material specification.
The API assay and related-substance requirements for the finished granules should be established using the validated analytical method applicable to the formulation.
Direct compression is a tablet manufacturing approach in which a suitable powder or granular blend is compressed directly into tablets without a conventional wet-granulation step. For an Atorvastatin DC Granules product, the granulated material is engineered to provide suitable handling and compression characteristics.
Research involving atorvastatin calcium tablets has evaluated direct-compression formulations and investigated physical tablet characteristics including hardness, friability and dissolution.
A separate study on atorvastatin oral dispersible tablets evaluated crystalline atorvastatin calcium with direct-compression fillers and reported that the formulation and filler system influenced tablet hardness, disintegration and dissolution.
These studies demonstrate the importance of formulation-specific material properties rather than assuming that the API alone determines direct-compression performance.
Particle-size distribution is an important quality attribute for Atorvastatin DC Granules. Consistent particle size can support controlled feeding, blending and compression behavior.
The finished product may be characterized using:
The appropriate numerical limits should be based on the actual approved product specification. D10, D50 and D90 values should not be invented for a commercial product page.
Flowability is important for consistent transfer and die filling during tablet manufacturing. Direct-compression formulations require a balance between flow, packing and compaction characteristics.
Atorvastatin DC Granules may therefore be evaluated using bulk density, tapped density, Carr Index, Hausner Ratio, angle of repose and flow-rate measurements where applicable.
Particle engineering and excipient selection are recognized as important factors in improving direct-compression performance.
The actual flow specifications should be established using the finished product's validated analytical procedures.
Compressibility describes the change in powder volume under pressure, while compactability relates to the ability of a material to form a mechanically strong compact.
These properties are particularly relevant for Atorvastatin DC Granules because the finished material is intended for compression-based manufacturing.
The formulation may be evaluated for:
These are finished-formulation performance attributes and should not be presented as universal specifications for every Atorvastatin DC Granules grade.
Uniform distribution of atorvastatin calcium throughout the granulated formulation is an important quality consideration, particularly when the active ingredient is present at relatively low concentration.
Blend uniformity can be evaluated using validated analytical procedures. Near-infrared spectroscopy has also been investigated as a real-time approach for monitoring blend uniformity in direct-compression and granulation-based products.
The actual sampling plan, acceptance criteria and analytical method should be defined within the approved manufacturing and quality-control procedures.
Atorvastatin calcium has formulation-dependent dissolution characteristics. Research involving direct-compression atorvastatin formulations has evaluated dissolution together with tablet mechanical properties.
The dissolution profile of Atorvastatin DC Granules depends on API characteristics, particle size, excipient composition, compression conditions and other formulation variables.
Therefore, specific dissolution percentages or time points should not be stated on the product page unless supported by the actual finished-product specification and validated dissolution method.
Moisture can influence the physical characteristics and processing behavior of pharmaceutical granules. For Atorvastatin DC Granules, moisture content should be controlled according to the approved product specification and supported by stability studies.
Packaging and storage requirements should be established based on validated stability data and the sensitivity of the finished formulation.
The finished product should be protected from environmental conditions that could affect API stability, granule flow or compression performance.
Quality control for Atorvastatin DC Granules should cover the identity, strength, purity and physical characteristics of the finished formulation.
Typical quality attributes may include:
USP-NF specifies 98.0–102.0% Atorvastatin Calcium for the API substance on an anhydrous and solvent-free basis. This API specification should not automatically be presented as the assay specification of the finished DC granules unless the finished-product method and specification use the same basis.
Atorvastatin DC Granules can be developed for oral solid dosage formulations where direct-compression processing is required.
Formulation development may investigate:
The selection and concentration of excipients should be established through formulation development and validated manufacturing studies.
Atorvastatin DC Granules may be considered for:
The final application and formulation performance should be established through product-specific development and validation.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white granules |